ArticleBMJ open gastroenterology2025
Assessment of adherence to guidelines for biochemical monitoring and ursodeoxycholic acid treatment response in a retrospective cohort of US patients with primary biliary cholangitis.
Article in BMJ open gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective.Journal of gastroenterology and hepatology · 2026Review
- What the European Reference Network Registry for Rare Liver Diseases Tells Us About Primary Biliary Cholangitis in European Practice.United European gastroenterology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAmerican Association for the Study of Liver Disease guidelines recommend regular testing of alkaline phosphatase (ALP) among patients with primary biliary cholangitis (PBC) to monitor disease progression and response to treatment with ursodeoxycholic acid (UDCA), but previous studies have shown that adherence to recommended testing intervals is low. We used data from the Fibrotic Liver Disease (FOLD) Consortium to evaluate rates of adherence among US routine care patients.
methodsPBC cases were confirmed with chart abstraction. Patients from three FOLD sites (Henry Ford Health (Detroit, MI), Kaiser Permanente-Southern California (Los Angeles, California) and Kaiser Permanente-Northwest (Portland, Oregon)) were observed from 1 January 2018 through 31 December 2021. We divided our evaluation of adherence to monitoring guidelines into two segments: (1) the first 12 months post-UDCA initiation; and (2) >12 months post-UDCA initiation.
resultsA total of 1756 patients were identified for the 2018-2021 period; 67 patients did not receive UDCA and were excluded from the sample. A total of 1689 patients were included in one or both segments (segment 1: 740, segment 2: 1689). Only 52% of patients received appropriate ALP testing to ascertain response to UDCA after roughly 1 year of treatment; rates were significantly higher among patients with specialist care compared with those without (54% vs 45%, p=0.001). For the period following the first year of UDCA treatment, the observed monitoring rate was 67%, where hepatology or gastroenterology specialist care was associated with significantly higher rates of monitoring (65%-78%) compared with those without care from a specialist (30%-57%, p<0.0001) with the same level of comorbidity.
conclusionIn a large US PBC cohort, there were concerning levels of non-adherence to recommended biochemical monitoring. Receipt of care from a specialist was associated with higher rates of monitoring. Strategies to increase rates of biochemical testing are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.